menu
    • menu
    [{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"M011","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"M041","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"M041","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"M011","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by M6P Therapeutics

    Menu

    M6P Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M011

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 18th Annual WORLDSy...

                            Details : M011 is a novel recombinant human β-glucosidase (rhGCase) enzyme co-expressed with S1S3 PTase that produces rhGCase with a high M6P levels, resulting in high levels of bis-phosphorylated glycans and high binding affinity for the CI-MPR.

                            Brand Name : M011

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 11, 2022

                            Lead Product(s) : M011

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M041

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            M6P Therapeutics to Participate in Key Event Highlights at WORLDSymposium™ 2022 and Present Preclinical Data...

                            Details : Evidence that M041, phosphorylated alpha-N-acetylglucosaminidase, has improved trafficking and binding to M6P receptors. M041 has markedly improved cellular uptake in patient fibroblasts when compared to wild type alpha-N-acetylglucosaminidase.

                            Brand Name : M041

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 02, 2022

                            Lead Product(s) : M041

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M041

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            M6P Therapeutics Presented Data on M041

                            Details : As the study suggests, M6PT’s M041 recombinant enzyme therapy (NAGLUM6P) employs an efficient and well-trafficked lysosomal enzyme as the key to developing a potentially effective therapy to treat this rare pediatric disorder.

                            Brand Name : M041

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 28, 2021

                            Lead Product(s) : M041

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            M6P Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M011

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 17th Annual WORLDSy...

                            Details : M011, a highly phosphorylated recombinant β-glucosidase (GCase) enzyme with a high affinity for the cation independent mannose 6-phosphate receptor, demonstrated superiority to imiglucerase, in terms of binding to the CI-MPR and uptake by Gaucher patien...

                            Brand Name : M011

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            February 11, 2021

                            Lead Product(s) : M011

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth